Loading...
One of the challenges in drug pharmacology is understanding what determines the susceptibility of some patients to adverse reactions. Pharmacogenomics links genetics to drug pharmacodynamics; it is one of the primary ways of studying this risk. In this study, researchers conducted a pharmacogenomics study of patients in East and Southeast Asia with severe reactions to the antiseizure drug phenytoin: 48 with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and 42 with reactions with eosinophilia and systemic symptoms. The authors conducted a genome-wide association study (GWAS) comparing the patients' genomes with those of 130 phenytoin-tolerant controls and 412 healthy population controls.
The authors identified 16 loci associat…